Bloom Burton Cuts Earnings Estimates for AbCellera Biologics

AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Equities research analysts at Bloom Burton lowered their FY2025 EPS estimates for AbCellera Biologics in a report issued on Monday, March 3rd. Bloom Burton analyst D. Martin now forecasts that the company will post earnings of ($0.73) per share for the year, down from their previous forecast of ($0.52). The consensus estimate for AbCellera Biologics' current full-year earnings is ($0.59) per share. Bloom Burton also issued estimates for AbCellera Biologics' FY2026 earnings at ($0.76) EPS.

A number of other equities analysts have also recently issued reports on the stock. Benchmark reiterated a "hold" rating on shares of AbCellera Biologics in a research note on Monday, March 3rd. Stifel Nicolaus reduced their price target on shares of AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, February 28th. Finally, KeyCorp cut their target price on AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th.

AbCellera Biologics Price Performance

ABCL stock traded down $0.13 during midday trading on Thursday, hitting $2.20. The stock had a trading volume of 5,623,909 shares, compared to its average volume of 2,280,931. The business has a 50-day moving average of $3.04 and a two-hundred day moving average of $2.83. The firm has a market cap of $655.57 million, a price-to-earnings ratio of -3.61 and a beta of 0.45. AbCellera Biologics has a 52-week low of $2.18 and a 52-week high of $5.04.

Remove Ads

Hedge Funds Weigh In On AbCellera Biologics

Several hedge funds have recently bought and sold shares of ABCL. Squarepoint Ops LLC lifted its holdings in AbCellera Biologics by 333.1% during the fourth quarter. Squarepoint Ops LLC now owns 57,685 shares of the company's stock worth $169,000 after buying an additional 44,367 shares during the period. Two Sigma Advisers LP boosted its holdings in shares of AbCellera Biologics by 19.8% in the 4th quarter. Two Sigma Advisers LP now owns 2,608,400 shares of the company's stock valued at $7,643,000 after buying an additional 430,800 shares in the last quarter. Two Sigma Investments LP grew its position in shares of AbCellera Biologics by 28.6% in the 4th quarter. Two Sigma Investments LP now owns 3,257,311 shares of the company's stock worth $9,544,000 after buying an additional 723,676 shares during the last quarter. Tang Capital Management LLC raised its stake in shares of AbCellera Biologics by 12.3% during the 4th quarter. Tang Capital Management LLC now owns 2,582,816 shares of the company's stock worth $7,568,000 after acquiring an additional 282,816 shares in the last quarter. Finally, Millennium Management LLC lifted its position in AbCellera Biologics by 96.7% during the fourth quarter. Millennium Management LLC now owns 1,482,715 shares of the company's stock valued at $4,344,000 after acquiring an additional 728,828 shares during the last quarter. Institutional investors own 61.42% of the company's stock.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.